Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma

Future Oncology

Volumn 13, Issue 14, 2017, Pages 1263-1279

  Nghiem, Paul ^a   Kaufman, Howard L ^b   Bharmal, Murtuza ^c   Mahnke, Lisa ^d   Phatak, Hemant ^e   Becker, Jürgen C ^f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c MERCK KGAA   (Germany)

^d EMD SERONO INC   (United States)

^e US Health Economics and Outcomes Research EMD Serono   (United States)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

checkpoint inhibitors; chemotherapy; immunotherapy; Merkel cell carcinoma; metastasis; systematic literature review

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL; LOMUSTINE; MELPHALAN; METHOTREXATE; MITOXANTRONE; OCTREOTIDE; OTERACIL; PACLITAXEL; PAZOPANIB; PLATINUM; PREDNISOLONE; PREDNISONE; STREPTOZOCIN; TEGAFUR; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE;

ABDOMINAL PAIN; ALOPECIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CLINICAL OUTCOME; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY FAILURE; LEUKOPENIA; MERKEL CELL CARCINOMA; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARAPLEGIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SEPSIS; SEPTIC SHOCK; SKIN METASTASIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ADVERSE DRUG REACTION; METASTASIS; PATHOLOGY; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

CARCINOMA, MERKEL CELL; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 85021408026     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon-2017-0072     Document Type: Review

References (102)

1. Toker C. Trabecular carcinoma of the skin. Arch. Dermatol. 105(1), 107-110 (1972).
2. Saini AT, Miles BA. Merkel cell carcinoma of the head and neck: pathogenesis, current and emerging treatment options. Onco. Targets Ther. 8, 2157-2167 (2015).
3. Chen MM, Roman SA, Sosa JA, Judson BL. The role of adjuvant therapy in the management of head and neck Merkel cell carcinoma: An analysis of 4815 patients. JAMA Otolaryngol. Head Neck Surg. 141(2), 137-141 (2015).
4. Smith VA, Camp ER, Lentsch EJ. Merkel cell carcinoma: identification of prognostic factors unique to tumors located in the head and neck based on analysis of SEER data. Laryngoscope 122(6), 1283-1290 (2012).
5. Lemos BD, Storer BE, Iyer JG et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. J. Am. Acad. Dermatol. 63(5), 751-761 (2010).
6. Arora R, Chang Y, Moore PS. MCV and Merkel cell carcinoma: A molecular success story. Curr. Opin. Virol. 2(4), 489-498 (2012).
7. Becker JC, zur HA. Cells of origin in skin cancer. J. Invest. Dermatol. 134(10), 2491-2493 (2014).
8. Poulsen M. Merkel cell carcinoma of skin: diagnosis and management strategies. Drugs Aging 22(3), 219-229 (2005).
9. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319(5-6), 1096-1100 (2008).
10. Harms PW, Vats P, Verhaegen ME et al. The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma. Cancer Res. 75(18), 3720-3727 (2015).
11. Wong SQ, Waldeck K, Vergara IA et al. UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas. Cancer Res. 75(24), 5228-5234 (2015).
12. Goh G, Walradt T, Markarov V et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget 7(3), 3403-3415 (2016).
13. Heath M, Jaimes N, Lemos B et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: The AEIOU features. J. Am. Acad. Dermatol. 58(3), 375-381 (2008).
14. Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cellcarcinoma: prognosis and treatment of patients from a single institution. J. Clin. Oncol. 23(10), 2300-2309 (2005).
15. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual (7th Edition). 315-323 Springer International Publishing, NY, USA (2010).
16. Harms KL, Healy MA, Nghiem P et al. Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system. Ann. Surg. Oncol. 23(11), 3564-3571 (2016).
17. Aldabagh B, Joo J, Yu SS. Merkel cell carcinoma: current status of targeted and future potential for immunotherapies. Semin. Cutan. Med. Surg. 33(2), 76-82 (2014).
18. NCCN. Merkel cell carcinoma guidelines, Version I. www. nccn. org/professionals/physician-gls
19. Lebbe C, Becker JC, Grob JJ et al. Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur. J. Cancer 51(16), 2396-2403 (2015).
20. Tai PT, Yu E, Winquist E et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J. Clin. Oncol. 18(12), 2493-2499 (2000).
21. Bhatia S, Afanasiev O, Nghiem P. Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer. Curr. Oncol. Rep. 13(6), 488-497 (2011).
22. Santamaria-Barria JA, Boland GM, Yeap BY, Nardi V, Dias-Santagata D, Cusack JC Jr. Merkel cell carcinoma: 30 year experience from a single institution. Ann. Surg. Oncol. 20(4), 1365-1373 (2013).
23. The Cochrane Database of Systematic Reviews. www. cochranelibrary. com/cochranedatabase-of-systematic-reviews/
24. Database of Abstracts of Reviews of Effects. http://community. cochrane. org/
25. Orphanet website. www. orpha. net/consor/cgi-bin/index. php
26. GLOBOCAN. http://globocan. iarc. fr/Default. Aspx
27. Embase. Embase. com
28. American Academy of Dermatology. www. Aad. org/
29. American Head and Neck Society. www. Ahns. info/
30. American Society of Clinical Oncology. www. Asco. org/
31. British Association of Dermatologists. www. bad. org. uk/
32. European Association of Dermato Oncology. www. eado. org/
33. European Society for Medical Oncology. www. esmo. org/
34. European Cancer Congress. www. eccocongress. org/
35. International Federation of Head and Neck Oncologic Societies. www. ifhnos. org/home
36. International Society for Pharmacoeconomics and Outcomes Research. www. ispor. org/
37. The Society for Melanoma Research. www. societymelanomaresearch. org/
38. World Congress of Dermatology. http://derm2015. org/
39. Iyer JG, Blom A, Doumani R, Lewis C, Ma C. Response rate and durability of chemotherapy for metastatic Merkel cell carcinoma among 62 patients. Presented at: The American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, USA 30 May-3 June 2014.
40. Satpute S, Ammakkanavar NR, Einhorn LH. Role of platinum-based chemotherapy for Merkel cell tumor in adjuvant and metastatic settings. Presented at: The American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, USA, 30 May-3 June 2014.
41. Voog E, Biron P, Martin JP, Blay JY. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85(12), 2589-2595 (1999).
42. Sharma D, Flora G, Grunberg SM. Chemotherapy of metastatic Merkel cell carcinoma: case report and review of the literature. Am. J. Clin. Oncol. 14(2), 166-169 (1991).
43. Bourne RG, O'Rourke MG. Management of Merkel cell tumour. Aust. N. Z. J. Surg. 58(12), 971-974 (1988).
44. Boyle F, Pendlebury S, Bell D. Further insights into the natural history and management of primary cutaneous neuroendocrine (Merkel cell) carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 31(2), 315-323 (1995).
45. Crown J, Lipzstein R, Cohen S et al. Chemotherapy of metastatic Merkel cell cancer. Cancer Invest. 9(2), 129-132 (1991).
46. Fenig E, Lurie H, Sulkes A. The use of cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of Merkel cell carcinoma. Am. J. Clin. Oncol. 16(1), 54-57 (1993).
47. Feun LG, Savaraj N, Legha SS, Silva EG, Benjamin RS, Burgess MA. Chemotherapy for metastatic Merkel cell carcinoma. Review of the M. D. Anderson Hospital's experience. Cancer 62(4), 683-685 (1988).
48. Grosh WW, Giannone L, Hande KR, Johnson DH. Disseminated Merkel cell tumor. Treatment with systemic chemotherapy. Am. J. Clin. Oncol. 10(3), 227-230 (1987).
49. Pectasides D, Pectasides M, Psyrri A et al. Cisplatin-based chemotherapy for merkel cell carcinoma of the skin. Cancer Invest. 24(8), 780-785 (2006).
50. Redmond J III, Perry J, Sowray P, Vukelja SJ, Dawson N. Chemotherapy of disseminated Merkel-cell carcinoma. Am. J. Clin. Oncol. 14(4), 305-307 (1991).
51. Schlaak M, Podewski T, Von BW et al. Induction of durable responses by oral etoposide monochemotherapy in patients with metastatic Merkel cell carcinoma. Eur. J. Dermatol. 22(2), 187-191 (2012).
52. Tai P, Assouline A, Joseph K, Lian JD, Krzisch C. Salvage treatments for Merkel cell carcinoma of skin. Nowotwory J. Onccology 61(6), 548-553 (2011).
53. Wynne CJ, Kearsley JH. Merkel cell tumor. A chemosensitive skin cancer. Cancer 62(1), 28-31 (1988).
54. Barkdull GC, Healy JF, Weisman RA. Intracranial spread of Merkel cell carcinoma through intact skull. Ann. Otol. Rhinol. Laryngol. 113(9), 683-687 (2004).
55. Biver-Dalle C, Nguyen T, Touze A et al. Use of interferon-alpha in two patients with Merkel cell carcinoma positive for Merkel cell polyomavirus. Acta Oncol. 50(3), 479-480 (2011).
56. Calza L, Beltrami C, Manfredi R, Colangeli V, Freo E, Chiodo F. Merkel cell carcinoma in a human immunodeficiency virus-infected patient. Br. J. Dermatol. 146(5), 895-898 (2002).
57. Chang DT, Mancuso AA, Riggs CE Jr, Mendenhall WM. Merkel cell carcinoma ofthe skin with leptomeningeal metastases. Am. J. Otolaryngol. 26(3), 210-213 (2005).
58. Cusick L, Refsum SE. Merkel cell carcinoma of the breast: report of a case and review of the literature. Ulster Med. J. 73(2), 137-138 (2004).
59. Davids MS, Charlton A, Ng SS et al. Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma. J. Clin. Oncol. 27(26), e97-e100 (2009).
60. Gaba S, Chopra P, Pankaj P, Belho ES, Qadri AB, Aggarwal S. Merkel cell carcinoma-a rare cause of non-healing skin ulcer: A case report. J. Indian Med. Assoc. 110(7), 496-498 (2012).
61. Grenader T, Shavit L. Tumor lysis syndrome in a patient with Merkel cell carcinoma and provoked pathologic sequence of acute kidney injury, reduced clearance of carboplatin and fatal pancytopenia. Onkologie 34(11), 626-629 (2011).
62. Krejci K, Tomas T, Pavel H, Hana C, Marián H. Merkel cell carcinoma of the gluteal region with ipsilateral metastasis into the pancreatic graft of a patient after combined kidney-pancreas transplantation. Onkologie 33(10), 520-524 (2010).
63. Noell CM, Rose E, Nesbitt LT. Merkel cell carcinoma presenting as right leg edema in a multiple myeloma patient. J. Am. Acad. Dermatol. 71(2), e50-e52 (2014).
64. Orlova K, Markovich A, Orel N, Demidov L. Role of somatostatin analogues in the management of Merkel cell carcinoma: A case report. Presented at: The 9th Annual European Neuroendocrine Tumor Society Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. Copenhagen, Denmark, 7-9 March 2012.
65. Santos-Juanes J, Palomo C, Rodrigo L, Fernandez-Vega I. Anaemia due to gastric haemorrhage by a metastatic Merkel cell carcinoma. Prz. Gastroenterol. 10(4), 244-246 (2015).
66. Shah JM, Sundar G, Tan KB, Zee YK. Unusual Merkel cell carcinoma of the eyelid. Orbit 31(6), 425-427 (2012).
67. Tanemura A, Nakano M, Iwasaki T et al. An extremely rare case of Merkel cell carcinoma metastasized to the duodenum. Eur. J. Dermatol. 22(4), 568-570 (2012).
68. Waldmann V, Goldschmidt H, Jackel A et al. Transient complete remission of metastasized Merkel cell carcinoma by high-dose polychemotherapy and autologous peripheral blood stem cell transplantation. Br. J. Dermatol. 143(4), 837-839 (2000).
69. Wang LW, Walker BD, Omari A, Tay AE, Subbiah RN. Metastatic Merkel cell carcinoma of the heart. Eur. Heart J. 35(41), 2927 (2014).
70. Yamana N, Sueyama H, Hamada M. Cardiac metastasis from Merkel cell skin carcinoma. Int. J. Clin. Oncol. 9(3), 210-212 (2004).
71. Di BM, Bajetta E, Bochicchio AM et al. A Phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian trials in medical oncology (I. T. M. O.) Group. Ann. Oncol. 6(1), 77-79 (1995).
72. Savage P, Constenla D, Fisher C, Thomas JM, Gore ME. The natural history and management of Merkel cell carcinoma of the skin: A review of 22 patients treated at the Royal Marsden Hospital. Clin. Oncol. (R. Coll. Radiol.) 9(3), 164-167 (1997).
73. Iyer JG, Blom A, Doumani R et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 5(9), 2294-2301 (2016).
74. Cowey LC, Mahnke L, Espirito J et al. Real-world outcomes of patients with metastatic Merkel cell carcinoma treated with second-line or later chemotherapy in a community oncology setting in the United States (2016). www. ispor. org/research-pdfs/54/
75. Sabol AJ, Markovic S, Otley C, Price KAR. Benefit of chemotherapy (CT) in patients (pts) with Merkel cell carcinoma (MCC) with distant metastases (mets) and visceral organ involvement. J. Clin. Oncol. 34(Suppl.), Abstract e21000 (2016).
76. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Malaria and some polyomaviruses (SV40, BK, JC, and Merkel cell viruses). IARC Monogr. Eval. Carcinog. Risks Hum. 104, 9-350 (2014).
77. Paulson KG, Iyer JG, Blom A et al. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J. Invest. Dermatol. 133(3), 642-646 (2013).
78. Paulson KG, Iyer JG, Simonson WT et al. CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of Merkel cell carcinoma survival: A population-based study. Am. J. Clin. Pathol. 142(4), 452-458 (2014).
79. Sihto H, Bohling T, Kavola H et al. Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: A population-based study. Clin. Cancer Res. 18(10), 2872-2881 (2012).
80. Behr DS, Peitsch WK, Hametner C et al. Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas. Int. J. Clin. Exp. Pathol. 7(11), 7610-7621 (2014).
81. Lipson EJ, Vincent JG, Loyo M et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol. Res. 1(1), 54-63 (2013).
82. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33(17), 1974-1982 (2015).
83. Santarpia M, Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol. Med. 12(2), 74-78 (2015).
84. Zitvogel L, Kroemer G. Targeting PD-1/ PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1(8), 1223-1225 (2012).
85. Boyerinas B, Jochems C, Fantini M et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol. Res. 3(10), 1148-1157 (2015).
86. Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int. Immunol. 27(1), 39-46 (2015).
87. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
88. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123-135 (2015).
89. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372(21), 2018-2028 (2015).
90. Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, Phase II trial. Lancet Oncol. 16(8), 908-918 (2015).
91. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320-330 (2015).
92. No authors listed. Nivolumab Doubles Survival for Patients with HNSCC. Cancer Discov. 6(7), OF3 (2016).
93. Addeo R, Caraglia M, Iuliano G. Pembrolizumab: The value of PDL1 biomarker in head and neck cancer. Expert Opin. Biol. Ther. 16(9), 1075-1078 (2016).
94. Afanasiev OK, Yelistratova L, Miller N et al. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin. Cancer Res. 19(19), 5351-5360 (2013).
95. Kaufman HL, Russell J, Hamid O et al. Avelumab in patients with chemotherapyrefractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, Phase II trial. Lancet Oncol. 17(10), 1374-1385 (2016).
96. Nghiem PT, Bhatia S, Lipson EJ et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N. Engl. J. Med. 374(26), 2542-2552 (2016).
97. Clinical Trials Database: NCT02196961. https. //clinicaltrials. gov/ct2
98. Bhatia S, Iyer I, Ibrani D et al. E. Intratumoral delivery of Interleukin-12 DNA via in vivo electroporation leads to regression of injected and non-injected tumors in Merkel cell carcinoma. Final results of a Phase II study. E. Congress Annual Meeting J. Cancer 51(supplement 3), Abstract 504.
99. Allen PJ, Zhang ZF, Coit DG. Surgical management of Merkel cell carcinoma. Ann. Surg. 229(1), 97-105 (1999).
100. Clark JR, Veness MJ, Gilbert R, O'Brien CJ, Gullane PJ. Merkel cell carcinoma of the head and neck: is adjuvant radiotherapy necessary Head Neck 29(3), 249-257 (2007).
101. Greene FL, Page DL, Fleming ID et al. AJCC Cancer Staging Manual (6th Edition). Springer International Publishing, NY, USA (2002).
102. Yiengpruksawan A, Coit DG, Thaler HT, Urmacher C, Knapper WK. Merkel cell carcinoma. Prognosis and management. Arch. Surg. 126(12), 1514-1519 (1991).